European Biotechs Mull Going To Market Without Big Pharma Partners
European biotech companies that have lead products turned down by big pharma are now considering the benefits of taking drugs through late-stage development themselves; more funding options, such as concluding an IPO in the U.S. or Europe, is driving some of this change.
You may also be interested in...
Nabriva Refreshes Lefamulin Strategy With New CEO, U.S. Office
The Vienna-based biotech looks to U.S. expertise to develop new mechanism-of-action antibacterial in go-it-alone strategy.
France's Adocia Completes 2012's First Euro Biotech IPO
French drug delivery company, Adocia, raises $33 million to develop new formulations of therapeutic proteins for wound healing, diabetes
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.